Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988138 | 0.78 | FFAR1 (0.65) | FFAR1FFAR4LTA4HEPHX2KMT2A | |
| SCHEMBL8008459 | 0.77 | FFAR1 (0.63) | FFAR1FFAR4LTA4HEPHX2KMT2A | |
| SCHEMBL7102376 | 0.75 | ALOX5 (0.45) | MRGPRX4FFAR1GRM2 | |
| SCHEMBL5880785 | 0.74 | S1PR1 (0.56) | MRGPRX4FFAR1FFAR4 | |
| SCHEMBL17141416 | 0.73 | MRGPRX4 (0.54) | MRGPRX4LTA4HEPHX2PTPRZ1GRM2 | |
| SCHEMBL11232868 | 0.71 | MAOB (0.62) | MRGPRX4PTPRZ1GRM2 | |
| SCHEMBL171861 | 0.71 | MRGPRX4 (0.47) | MRGPRX4PTPRZ1GRM2 | |
| SCHEMBL5880919 | 0.70 | MRGPRX4 (0.34) | MRGPRX4LTA4HEPHX2FAAHGRM2 | |
| SCHEMBL5880817 | 0.70 | ALDH1A1 (0.48) | FFAR1FFAR4HCAR2MEN1KMT2A | |
| SCHEMBL5880832 | 0.70 | LMNA (0.63) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | MRGPRX4 3682/4885FFAR1 3595/4885FFAR4 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.